Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409356 | 1.00 | EGFR (0.58) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Hydrochloric Acid SCHEMBL30749417 | 0.98 | EGFR (0.56) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Hydrochloric Acid SCHEMBL30749407 | 0.98 | EGFR (0.56) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Formic Acid SCHEMBL30064211 | 0.88 | EGFR (0.47) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL29409337 | 0.83 | EGFR (0.60) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL137377 | 0.83 | EGFR (0.60) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL1533934 | 0.82 | EGFR (0.55) | EGFRMKNK2CLK1PIK3CDPIK3CA | |
| Trifluoroacetic Acid SCHEMBL30749397 | 0.82 | EGFR (0.42) | EGFRKDM4C | |
| Isoquinoline SCHEMBL15549866 | 0.81 | EGFR (0.77) | EGFRMKNK2CLK1PIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL322987 | 0.81 | EGFR (0.58) | EGFRMKNK2CSNK1DCSNK1ECLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | claimed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | claimed |
| US-20230120564-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | claimed |
| EP-4105213-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | Korea Institute of Science and Technology (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | claimed |
| EP-3967687-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2022-03-16 | — | — | EP | claimed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | claimed |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | claimed |
| WO-2021145521-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | 한국과학기술연구원 | 2021-07-22 | — | — | WO | claimed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| EP-0861253-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-02 | — | — | EP | claimed |
| WO-1997026259-A1 | IMPROVED PROCESS FOR PREPARING 4,6-DISUBSTITUTED PYRIDO[3,4-d]PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | claimed |
| WO-1997013771-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-04-17 | — | — | WO | claimed |
| EP-0414386-A1 | Condensed pyrimidine derivates | DowElanco (US) | 1991-02-27 | — | — | EP | claimed |
| EP-0145337-B1 | ELECTROCHROMIC DEVICES | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1990-08-08 | — | — | EP | claimed |
| EP-0096723-B1 | BATTERIES FABRICATED WITH ELECTROACTIVE POLYMERS | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1988-08-10 | — | — | EP | claimed |
| US-4613211-A | REVERSE COLOR CHANGING POLYMER FILM AS DISPLAY ELECTRODE | CHEVRON RESEARCH COMPANY (US) | 1986-09-23 | — | — | US | claimed |
| US-4579679-A | Electroactive polymers | CHEVRON RESEARCH COMPANY (US) | 1986-04-01 | — | — | US | claimed |
| EP-0145337-A2 | Electrochromic devices | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1985-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | EGFR 88/4885MKNK2 1052/4885CSNK1D 359/4885 |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | EGFR 669/4885MKNK2 1007/4885CSNK1D 68/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | EGFR 539/4885MKNK2 259/4885CSNK1D 305/4885 |
| US-20230120564-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | DPYD, WEE1, CDK4 | EGFR 2558/4885MKNK2 3698/4885CSNK1D 1177/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | EGFR 204/4885MKNK2 810/4885CSNK1D 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.